OTLK — Outlook Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $50.56m
- $75.60m
Annual cashflow statement for Outlook Therapeutics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.2 | -53.2 | -66.1 | -59 | -75.4 |
| Depreciation | |||||
| Non-Cash Items | 4.17 | 5.73 | 10.9 | 12.4 | 9.48 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.27 | -7.08 | -1.68 | 3.59 | -3.02 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -31.8 | -54.3 | -56.7 | -43 | -68.8 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.9 | 0 | — | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.9 | 0 | — | — | — |
| Financing Cash Flow Items | — | -0.008 | -0.6 | -0.824 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 37.2 | 56.2 | 59.6 | 49 | 60.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.52 | 1.94 | 2.92 | 6 | -8.46 |